Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
NCT03029338Phase 1Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2017
- Primary completion
- May 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UCD19 CAR-T in B-cell non-Hodgkin lymphoma, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Number of patients with adverse events at 2 years. Started Jun 2017; status: completed.
02
Drugs
UCD19 CAR-T
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03029338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029338.